Condition Lookup
Sub-Category:
Metabolic and Genetic Cardiovascular Disorders
Number of Conditions: 4
Cardiac Amyloidosis
Specialty: Cardiovascular
Category: Other Cardiovascular Conditions
Sub-category: Metabolic and Genetic Cardiovascular Disorders
Symptoms:
shortness of breath; swelling in legs and feet (edema); fatigue; irregular heartbeat; difficulty exercising; low blood pressure; chest pain
Root Cause:
Deposition of amyloid protein in the heart, leading to stiffened heart walls and impaired heart function.
How it's Diagnosed: videos
Echocardiography, cardiac MRI, endomyocardial biopsy, blood tests (e.g., serum free light chain assay), and imaging with technetium-labeled radiotracers. Genetic testing may be performed for hereditary forms.
Treatment:
Includes addressing heart failure symptoms, halting amyloid protein deposition, and organ transplantation in advanced cases.
Medications:
Tafamidis (stabilizes transthyretin amyloid proteins), diuretics (e.g., furosemide , to manage fluid buildup), and anticoagulants (e.g., warfarin , if atrial fibrillation is present). Tafamidis is a transthyretin stabilizer; diuretics are used for symptom management, and anticoagulants prevent blood clots.
Prevalence:
How common the health condition is within a specific population.
Rare; transthyretin amyloidosis (ATTR) affects approximately 1 in 100,000 people, with higher prevalence in older adults and certain populations.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Advanced age, male sex, African or Mediterranean ancestry, family history of amyloidosis, chronic inflammatory diseases.
Prognosis:
The expected outcome or course of the condition over time.
Variable; depends on the type and extent of amyloidosis. Prognosis improves with early diagnosis and treatment. Without treatment, progression leads to heart failure and poor outcomes.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Heart failure, arrhythmias, thromboembolism, sudden cardiac death.
Hemochromatosis-Related Cardiomyopathy
Specialty: Cardiovascular
Category: Other Cardiovascular Conditions
Sub-category: Metabolic and Genetic Cardiovascular Disorders
Symptoms:
fatigue; shortness of breath; chest pain; palpitations; edema in legs; irregular heartbeat; signs of heart failure
Root Cause:
Excessive iron deposition in the heart muscle, leading to oxidative damage, fibrosis, and impaired heart function.
How it's Diagnosed: videos
Blood tests (serum ferritin, transferrin saturation), genetic testing (HFE gene mutations), cardiac MRI (to assess iron overload), echocardiography, and liver biopsy (to confirm systemic iron overload).
Treatment:
Iron removal through phlebotomy or chelation therapy, and management of heart failure symptoms.
Medications:
Deferoxamine , deferasirox , or deferiprone (iron chelators). These are used to reduce iron overload in patients who cannot undergo phlebotomy. Diuretics and beta-blockers may also be used to manage heart failure symptoms.
Prevalence:
How common the health condition is within a specific population.
Hemochromatosis affects approximately 1 in 200–300 individuals of European descent; cardiomyopathy develops in a subset of untreated cases.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Genetic predisposition (HFE gene mutations), male sex, excessive alcohol consumption, metabolic syndrome.
Prognosis:
The expected outcome or course of the condition over time.
Good if diagnosed and treated early; untreated cases can lead to severe heart failure and other organ damage.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Heart failure, arrhythmias, liver cirrhosis, diabetes, hypogonadism.
Fabry Disease
Specialty: Cardiovascular
Category: Other Cardiovascular Conditions
Sub-category: Metabolic and Genetic Cardiovascular Disorders
Symptoms:
pain in hands and feet; decreased sweating; heat and cold intolerance; fatigue; angiokeratomas (dark skin spots); proteinuria; shortness of breath; cardiomyopathy; arrhythmias
Root Cause:
X-linked lysosomal storage disorder caused by mutations in the GLA gene, leading to deficient alpha-galactosidase A activity and accumulation of globotriaosylceramide (GL3/Gb3) in tissues, including the heart.
How it's Diagnosed: videos
Enzyme assay (alpha-galactosidase A activity), genetic testing (GLA mutation), urine tests (for GL3 levels), echocardiography, cardiac MRI, and biopsy.
Treatment:
Enzyme replacement therapy (ERT) or chaperone therapy, supportive care for symptoms, and management of cardiac and renal complications.
Medications:
Agalsidase alfa or beta (enzyme replacement therapy), migalastat (chaperone therapy). Diuretics and ACE inhibitors are used for heart and kidney complications, respectively. ERT replaces deficient enzymes; migalastat stabilizes mutant enzymes in eligible patients.
Prevalence:
How common the health condition is within a specific population.
Rare, estimated at 1 in 40,000 to 1 in 60,000 males; females can be carriers or mildly symptomatic.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history, X-linked inheritance (affects males more severely).
Prognosis:
The expected outcome or course of the condition over time.
Improved with early diagnosis and treatment. Untreated cases may lead to progressive kidney failure, heart disease, and stroke.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Hypertrophic cardiomyopathy, arrhythmias, stroke, kidney failure.
Pompe Disease
Specialty: Cardiovascular
Category: Other Cardiovascular Conditions
Sub-category: Metabolic and Genetic Cardiovascular Disorders
Symptoms:
muscle weakness; difficulty breathing; enlarged heart (in infantile-onset); fatigue; exercise intolerance; respiratory failure
Root Cause:
Autosomal recessive lysosomal storage disorder caused by mutations in the GAA gene, resulting in deficient acid alpha-glucosidase enzyme and glycogen accumulation in tissues, including the heart and skeletal muscles.
How it's Diagnosed: videos
Enzyme assay (acid alpha-glucosidase activity), genetic testing (GAA mutation), muscle biopsy, and imaging studies (e.g., echocardiography in infantile-onset cases).
Treatment:
Enzyme replacement therapy (ERT) and supportive care, including respiratory support and physical therapy.
Medications:
Alglucosidase alfa (enzyme replacement therapy). ERT replaces the deficient enzyme to reduce glycogen accumulation in tissues. Additional medications may include bronchodilators and oxygen for respiratory support.
Prevalence:
How common the health condition is within a specific population.
Estimated at 1 in 40,000 births globally; varies by population and ethnicity.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Genetic predisposition (autosomal recessive inheritance), family history.
Prognosis:
The expected outcome or course of the condition over time.
Variable; infantile-onset cases have poor outcomes without treatment, but ERT significantly improves survival and quality of life. Late-onset cases progress more slowly.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Respiratory failure, heart failure (in infantile-onset), severe disability due to muscle weakness.